EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Martowicz, Agnieszka ^a   Rainer, Johannes ^a   Lelong, Julien ^a   Spizzo, Gilbert ^a   Gastl, Guenther ^a,b   Untergasser, Gerold ^b  

^a TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CAM model; EpCAM; p53; Primary mammary epithelial cells; Transforming growth factor beta

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; EPITHELIAL CELL ADHESION MOLECULE; PROTEIN P53; PROTEIN P63; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOLATERAL MEMBRANE; BREAST EPITHELIUM; BREAST HYPERPLASIA; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; BREAST; CADHERINS; CELL ADHESION MOLECULES; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; HYPERPLASIA; PRIMARY CELL CULTURE; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS;

EID: 84878744347     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-56     Document Type: Article

References (47)

1. Litvinov SV, Bakker HA, Gourevitch MM, Velders MP, Warnaar SO. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes Commun 1994, 2:417-428. 10.3109/15419069409004452, 7842256.
2. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994, 125:437-446. 10.1083/jcb.125.2.437, 2120036, 8163559.
3. Anderson R, Schaible K, Heasman J, Wylie C. Expression of the homophilic adhesion molecule, Ep-CAM, in the mammalian germ line. J Reprod Fertil 1999, 116:379-384. 10.1530/jrf.0.1160379, 10615264.
4. Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF, et al. Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem 2010, 285:8719-8732. 10.1074/jbc.M109.077081, 2838295, 20064925.
5. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010, 31:1913-1921. 10.1093/carcin/bgq187, 20837599.
6. Slanchev K, Carney TJ, Stemmler MP, Koschorz B, Amsterdam A, Schwarz H, et al. The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development. PLoS Genet 2009, 5:e1000563. 10.1371/journal.pgen.1000563, 2700972, 19609345.
7. Nagao K, Zhu J, Heneghan MB, Hanson JC, Morasso MI, Tessarollo L, et al. Abnormal placental development and early embryonic lethality in EpCAM-null mice. PLoS One 2009, 4:e8543. 10.1371/journal.pone.0008543, 2796178, 20046825.
8. Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 2011, 12:49-55. 10.1016/S1470-2045(10)70265-5, 3670774, 21145788.
9. Basak S, Speicher D, Eck S, Wunner W, Maul G, Simmons MS, et al. Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst 1998, 90:691-697. 10.1093/jnci/90.9.691, 9586666.
10. Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH, Litvinov SV. Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 2003, 285:50-58. 10.1016/S0014-4827(02)00045-9, 12681286.
11. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009, 11:162-171. 10.1038/ncb1824, 19136966.
12. Schmidt M, Scheulen ME, Dittrich C, Obrist P, Marschner N, Dirix L, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010, 21:275-282. 10.1093/annonc/mdp314, 19633042.
13. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000, 356:1981-1982. 10.1016/S0140-6736(00)03312-2, 11130529.
14. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004, 86:207-213. 10.1023/B:BREA.0000036787.59816.01, 15567937.
15. Schmidt M, Ruttinger D, Sebastian M, Hanusch CA, Marschner N, Baeuerle PA, et al. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol 2012, 9:2306-2313.
16. Bokemeyer C. Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther 2010, 10:1259-1269. 10.1517/14712598.2010.504706, 20624115.
17. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 1999, 77:699-712.
18. Martowicz A, Spizzo G, Gastl G, Untergasser G. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer 2012, 12:501. 10.1186/1471-2407-12-501, 3519683, 23110550.
19. Untergasser G, Steurer M, Zimmermann M, Hermann M, Kern J, Amberger A, et al. The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer 2008, 122:1539-1547.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
21. Rainer J, Lelong J, Bindreither D, Mantinger C, Ploner C, Geley S, et al. Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia. Mol Endocrinol 2012, 26:178-193. 10.1210/me.2011-1213, 22074950.
22. Chen HF, Chuang CY, Lee WC, Huang HP, Wu HC, Ho HN, et al. Surface marker epithelial cell adhesion molecule and E-cadherin facilitate the identification and selection of induced pluripotent stem cells. Stem Cell Rev 2011, 7:722-735. 10.1007/s12015-011-9233-y, 21305366.
23. Gonzalez B, Denzel S, Mack B, Conrad M, Gires O. EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells 2009, 27:1782-1791. 10.1002/stem.97, 19544432.
24. Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012, 30:292-303. 10.1002/stem.791, 22102611.
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
26. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69:5627-5629. 10.1158/0008-5472.CAN-09-0654, 19584271.
27. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004, 64:5818-5824. 10.1158/0008-5472.CAN-04-0754, 15313925.
28. Schmelzer E, Reid LM. EpCAM expression in normal, non-pathological tissues. Front Biosci 2008, 13:3096-3100. 10.2741/2911, 17981779.
29. Carpenter G, Red BM. EpCAM: another surface-to-nucleus missile. Cancer Cell 2009, 15:165-166. 10.1016/j.ccr.2009.02.005, 19249674.
30. Munz M, Fellinger K, Hofmann T, Schmitt B, Gires O. Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM. Front Biosci 2008, 13:5195-5201.
31. Winter MJ, Cirulli V, Briaire-de Bruijn IH, Litvinov SV. Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase. Mol Cell Biochem 2007, 302:19-26. 10.1007/s11010-007-9420-y, 17646933.
32. Garbe JC, Holst CR, Bassett E, Tlsty T, Stampfer MR. Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis. Cell Cycle 2007, 6:1927-1936. 10.4161/cc.6.15.4519, 17671422.
33. Garbe JC, Bhattacharya S, Merchant B, Bassett E, Swisshelm K, Feiler HS, et al. Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer Res 2009, 69:7557-7568. 10.1158/0008-5472.CAN-09-0270, 2782785, 19773443.
34. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010, 10:51-57. 10.1038/nrc2772, 3672965, 20029423.
35. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602. 10.1016/S0092-8674(00)81902-9, 9054499.
36. Stampfer MR, Garbe J, Levine G, Lichtsteiner S, Vasserot AP, Yaswen P. Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc Natl Acad Sci USA 2001, 98:4498-4503. 10.1073/pnas.071483998, 31863, 11287649.
37. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE. Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res 2009, 69:753-757. 10.1158/0008-5472.CAN-08-2708, 19141643.
38. Boehme KA, Blattner C. Regulation of p53-insights into a complex process. Crit Rev Biochem Mol Biol 2009, 44:367-392. 10.3109/10409230903401507, 19929178.
39. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004, 18:862-876. 10.1101/gad.1185504, 395846, 15078817.
40. Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U, et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 2013, 32:641-650. 10.1038/onc.2012.75, 22391566.
41. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004, 23:5748-5758. 10.1038/sj.onc.1207610, 15195135.
42. Kuhn S, Koch M, Nubel T, Ladwein M, Antolovic D, Klingbeil P, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007, 5:553-567. 10.1158/1541-7786.MCR-06-0384, 17579117.
43. Maghzal N, Vogt E, Reintsch W, Fraser JS, Fagotto F. The tumor-associated EpCAM regulates morphogenetic movements through intracellular signaling. J Cell Biol 2010, 191:645-659. 10.1083/jcb.201004074, 3003323, 20974811.
44. Untergasser G, Koch HB, Menssen A, Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res 2002, 62:6255-6262.
45. Untergasser G, Gander R, Rumpold H, Heinrich E, Plas E, Berger P. TGF-beta cytokines increase senescence-associated beta-galactosidase activity in human prostate basal cells by supporting differentiation processes, but not cellular senescence. Exp Gerontol 2003, 38:1179-1188. 10.1016/j.exger.2003.08.008, 14580871.
46. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296:1046-1049. 10.1126/science.1067431, 2788989, 12004111.
47. Gaiser MR, Lammermann T, Feng X, Igyarto BZ, Kaplan DH, Tessarollo L, et al. Cancer-associated epithelial cell adhesion molecule (EpCAM; CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc Natl Acad Sci USA 2012, 109:E889-E897. 10.1073/pnas.1117674109, 3326512, 22411813.